MARKET

TEVA

TEVA

Teva Pharm
NYSE

Real-time Quotes | Nasdaq Last Sale

7.74
+0.07
+0.91%
After Hours: 7.78 +0.04 +0.52% 19:59 06/24 EDT
OPEN
7.77
PREV CLOSE
7.67
HIGH
7.81
LOW
7.68
VOLUME
19.36M
TURNOVER
0
52 WEEK HIGH
10.50
52 WEEK LOW
7.23
MARKET CAP
8.59B
P/E (TTM)
-13.8959
1D
5D
1M
3M
1Y
5Y
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)
AMSTERDAM, June 24, 2022--Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria.
Business Wire · 2d ago
Teva Lonquex gets EMA panel backing for expanded use in children
A committee of the European Medicines Agency (EMA) recommended the approval of expanded use of Teva Pharmaceutical's (NYSE:TEVA) Lonquex for children two years of age and older to treat a side effect of chemotherapy.
Seekingalpha · 2d ago
Teva Pharmaceutical's Unit Says Initial Ajovy Data Shows Reduction in Monthly Migraine Days
MT Newswires · 2d ago
Teva started at neutral at UBS on pricing and legal concerns
UBS has initiated Teva Pharmaceutical Industries (NYSE:TEVA) with a neutral rating saying that the Israeli drugmaker is facing "price deterioration and overcrowding." The firm has a $10 price target (~27%
Seekingalpha · 06/14 16:18
Analyst Ratings for Teva Pharmaceutical Indus
Within the last quarter, Teva Pharmaceutical Indus (NYSE:TEVA) has observed the following analyst ratings:
Benzinga · 06/14 14:04
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades
Benzinga · 06/14 14:03
Teva Pharmaceutical Affiliates Settle With Aurobindo Resolving Austedo Patent Dispute
MT Newswires · 06/10 04:28
Teva settles patent dispute with India's Aurobindo over its Austedo medicine
Teva Pharmaceutical Industries (NYSE:TEVA) on Thursday announced a settlement with India's Aurobindo Pharma over a patent dispute regarding Teva's medicine Austedo. The agreement was reached between Aurobindo and Teva's U.S.
Seekingalpha · 06/09 21:32
More
No Data
Learn about the latest financial forecast of TEVA. Analyze the recent business situations of Teva Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
7.14%Buy
85.71%Hold
7.14%Under-perform
0.00%Sell
Analyst Price Target
The average TEVA stock price target is 10.11 with a high estimate of 13.00 and a low estimate of 7.00.
High13.00
Average10.11
Low7.00
Current 7.74
EPS
Actual
Estimate
0.190.390.580.77
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 704
Institutional Holdings: 552.95M
% Owned: 49.80%
Shares Outstanding: 1.11B
TypeInstitutionsShares
Increased
135
32.14M
New
42
5.79M
Decreased
115
22.40M
Sold Out
52
5.07M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+2.68%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Non-Executive Chairman/Independent Director
Sol Barer
President/Chief Executive Officer/Director
Kaare Schultz
Chief Financial Officer/Executive Vice President
Eliyahu Kalif
Chief Human Resource Officer/Executive Vice President
Galia Inbar
Executive Vice President
Richard Daniell
Executive Vice President
Sven Dethlefs
Executive Vice President
Eric Drape
Executive Vice President
Hafrun Fridriksdottir
Executive Vice President
Mark Sabag
Executive Vice President
Eli Shani
Executive Vice President
David Stark
Independent Director
Rosemary Crane
Independent Director
Amir Elstein
Independent Director
Jean-Michel Halfon
Independent Director
Gerald Lieberman
Independent Director
Roberto Mignone
Independent Director
Perry Nisen
Independent Director
Nechemia Peres
Independent Director
Ronit Satchi-Fainaro
Independent Director
Janet Vergis
Independent Director
Tal Zvi Zaks
No Data
No Data
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Webull offers kinds of Teva Pharmaceutical Industries Ltd (ADR) stock information, including NYSE:TEVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TEVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TEVA stock methods without spending real money on the virtual paper trading platform.